Hexima Ltd (ASX:HXL) Share Price & Analysis

Hexima Limited (ASX: HXL) is an Australian-based biotechnology company headquartered in Melbourne that is currently listed on the Australian Securities Exchange. Established in 1998, the company was originally founded to commercialize discoveries related to plant-derived proteins and peptides with potent antifungal properties. For much of its history, the entity operated as a clinical-stage developer of human therapeutics, leveraging intellectual property developed in collaboration with leading Australian academic institutions.

The company’s operational history was centered on its lead drug candidate, pezadeftide (HXP124), which was developed as a novel topical treatment for onychomycosis, a common fungal nail infection. Despite progressing through Phase IIb clinical trials, the company ceased its primary research and development activities after failing to meet certain clinical objectives. Consequently, Hexima’s current operations are limited to the maintenance of its remaining intellectual property portfolio and the management of its corporate structure while it remains in a period of transition.

Hexima’s current strategic objective is to identify and execute a corporate transaction, such as a reverse merger or acquisition, that can provide a new business direction and create value for its shareholders. While the company’s securities are presently suspended from quotation on the ASX following the cancellation of a proposed acquisition in late 2024, the board remains active in evaluating third-party opportunities. The entity continues to fulfill its regulatory reporting obligations as it seeks a suitable partner to facilitate its return to active commercial operations.